Biomedicines (Sep 2022)

A Protein Microarray-Based Respiratory Viral Antigen Testing Platform for COVID-19 Surveillance

  • Sungjun Beck,
  • Rie Nakajima,
  • Algis Jasinskas,
  • Timothy J. Abram,
  • Sun Jin Kim,
  • Nader Bigdeli,
  • Delia F. Tifrea,
  • Jenny Hernandez-Davies,
  • D. Huw Davies,
  • Per Niklas Hedde,
  • Philip L. Felgner,
  • Weian Zhao

DOI
https://doi.org/10.3390/biomedicines10092238
Journal volume & issue
Vol. 10, no. 9
p. 2238

Abstract

Read online

High-throughput and rapid screening testing is highly desirable to effectively combat the rapidly evolving COVID-19 pandemic co-presents with influenza and seasonal common cold epidemics. Here, we present a general workflow for iterative development and validation of an antibody-based microarray assay for the detection of a respiratory viral panel: (a) antibody screening to quickly identify optimal reagents and assay conditions, (b) immunofluorescence assay design including signal amplification for low viral titers, (c) assay characterization with recombinant proteins, inactivated viral samples and clinical samples, and (d) multiplexing to detect a panel of common respiratory viruses. Using RT-PCR-confirmed SARS-CoV-2 positive and negative pharyngeal swab samples, we demonstrated that the antibody microarray assay exhibited a clinical sensitivity and specificity of 77.2% and 100%, respectively, which are comparable to existing FDA-authorized antigen tests. Moreover, the microarray assay is correlated with RT-PCR cycle threshold (Ct) values and is particularly effective in identifying high viral titers. The multiplexed assay can selectively detect SARS-CoV-2 and influenza virus, which can be used to discriminate these viral infections that share similar symptoms. Such protein microarray technology is amenable for scale-up and automation and can be broadly applied as a both diagnostic and research tool.

Keywords